A G-protein activation cascade from Arl13B to Arl3 and implications for ciliary targeting of lipidated proteins

Authors
Katja Gotthardt¹*, Mandy Lokaj¹§, Carolin Koerner¹, Nathalie Falk², Andreas Gießl², Alfred Wittinghofer¹

Institute
¹Structural Biology Group, Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany
²Department of Biology, Animal Physiology, University of Erlangen-Nuremberg, D-91054 Erlangen, Germany

*These authors contributed equally to this work
§ corresponding authors
Abstract

Small G-proteins of the ADP-ribosylation-factor-like (Arl) subfamily have been shown to be crucial to ciliogenesis and cilia maintenance. Active Arl3 is involved in targeting and releasing lipidated cargo proteins from their carriers PDE6δ and UNC119a/b to the cilium. However, the Guanine-Nucleotide-Exchange-factor (GEF) which activates Arl3 is unknown. Here we show that the ciliary G-protein Arl13B mutated in Joubert-Syndrome is the GEF for Arl3 and its function is conserved in evolution. The GEF activity of Arl13B is mediated by the G-domain plus an additional C-terminal helix. The switch regions of Arl13B are involved in the interaction with Arl3. Overexpression of Arl13B in mammalian cell lines leads to an increased Arl3•GTP level, whereas Arl13B Joubert-Syndrome patient mutations impair GEF activity and thus Arl3 activation. We anticipate that through Arl13B’s exclusive ciliary localization, Arl3 activation is spatially restricted and thereby an Arl3•GTP compartment generated where ciliary cargo is specifically released.
Introduction

Primary cilia are highly conserved organelles essential for developmental signalling pathways and cellular homeostasis. The small G-proteins of the Arl family Arl3, Arl6 and Arl13B have been shown to be important in trafficking of ciliary proteins and structural integrity of the cilium (Li et al., 2012). Mutations in Arl proteins or their regulators can lead to cilia dysfunction causing ciliopathies such as Joubert Syndrome (JS), Bardet-Biedl-Syndrome (BBS) or Retinitis Pigmentosa (RP) (Cantagrel et al., 2008; Chiang et al., 2004; Schwahn et al., 1998). Different ciliopathies are characterized by overlapping phenotypes such as renal cysts, polydactyly, brain malfunction, situs inversus and vision impairment (Waters and Beales, 2011). Mutations in Arl6 –the first member of the Arl family found mutated in a human ciliopathy – cause Bardet-Biedl Syndrome, whereas mutations in Arl13B lead to Joubert Syndrome. Joubert Syndrome in particular is characterized by a brain malformation with a characteristic molar tooth sign combined with polydactyly and kidney cysts. Although no mutations in Arl3 have been identified so far in ciliopathies Arl3<sup>−/−</sup> mice exhibit a ciliopathy related phenotype and die by 3 weeks of age (Schrick et al., 2006). One of the X-linked retinitis pigmentosa genes is RP2 which functions as a GTPase activating protein (GAP) specific for Arl3 (Veltel et al., 2008).

As most small G-proteins Arl3 cycles between inactive GDP-bound and active GTP-bound forms and in the latter it binds specifically to effectors (Cherfils and Zeghouf, 2013). Effectors of Arl3 are the carrier proteins PDE6δ, which binds farnesylated and geranylgeranylated cargo, and Unc119a/b which binds myristoylated cargo. Binding of activated Arl3 to the cargo-carrier complex induces conformational changes leading to the release of the cargo (Ismail et al., 2012, 2011; Wright et al., 2011). A close structural homologue of Arl3 is Arl2, which binds to the same set of effectors (Van Valkenburgh et al., 2001). However, while Arl2 and Arl3 can release cargo such as Ras or RheB, only Arl3 is able to release ciliary cargo such as INPP5E, NPHP3 and GNAT-1 (Ismail et al., 2012; Thomas et al., 2014; Wright et al., 2011). The highly conserved Arl3 – only present in ciliated organisms – localizes throughout the cell and is enriched in the primary cilium (Avidor-Reiss et al., 2004; Blacque et al., 2005; Zhou et al., 2006). While RP2 functions as an Arl3 GAP and is thus important for the import of lipiddated cargo by recycling Arl3 and its effectors (Schwarz et al., 2012; Wright et al., 2011; Zhang et al., 2015), the GEF that activates Arl3 remains unknown. We had anticipated that in order for Arl3 to mediate cargo release inside cilia, an Arl3-specific GEF should be localized there as well.
**Results**

To identify regulatory proteins of Arl3 we employed a yeast-2-hybrid (Y2H) screen using the fast cycling mutant Arl3ΔND129N as bait. The homologous mutation which in Ras was shown to decrease nucleotide and to increase GEF affinity while maintaining its ability to bind to effectors was used by us to identify the GEF for the plant specific ROP proteins (Berken et al., 2005; Cool et al., 1999). Screening a mouse retinal cDNA Y2H library identified several clones growing on selective media. Sequence analysis revealed Arl13B (residues 1-270) in addition to known Arl3 effectors such as PDE6δ and Unc119a. Intriguingly, in a parallel screen with mouse Arl13B20-278 as bait Arl3 was found as rescuing clone. The interaction between Arl3 and Arl13B was further verified by directed 1:1 Y2H analysis (Figure 1A). Arl13B is an unusual Arl protein containing a C-terminal coiled-coil and proline rich region in addition to its G-domain (Figure 1C). The data show that the interaction is mediated by Arl13B’s G-domain and part of the coiled-coil region. To investigate the specificity of the Arl13B-Arl3 interaction we tested the related constructs of Arl2 and Arl6 neither of which enabled growth on selective medium (Figure 1B).

To verify this interaction in vitro, we tested purified proteins in a GST-pull-down assay. Due to better stability and purity of Arl13B from *Chlamydomonas reinhardtii* (*Cr*) the following experiments were performed with the homologous *Cr*-proteins purified from *E. coli*. We thus prepared *Cr*Arl13B18-278 (*Cr*Arl13B from now) analogous to mouse Arl13B18-278 used in the Y2H screen and tested its interaction with Glutathione-S-transferase(GST)-*Cr*Arl3 loaded with either GDP or GppNHp (a non-hydrolysable GTP analogue) (Figure 2A). *Cr*Arl13B•GppNHp but not *Cr*Arl13B•GDP bound to GST-*Cr*Arl3, and binding was slightly stronger to GST-*Cr*Arl3•GDP than to GST-*Cr*Arl3•GppNHp. These data show that the interaction between Arl3 and Arl13B is conserved between mouse and *Chlamydomonas*.

Since the rather weak interaction in the pull-down experiments and the nucleotide-independent binding suggested that Arl3 is not an effector for Arl13B, we turned our attention to a possible GEF function. As a ciliary protein Arl13B is a good, albeit as a G-protein, a very unusual candidate GEF for Arl3. The dissociation of a fluorescent GDP-analogue (mantGDP) from *Cr*Arl3 in the presence of excess of unlabelled GTP was monitored after adding *Cr*Arl13B•GTP. The nucleotide dissociation was strikingly accelerated in the presence of *Cr*Arl13B•GTP and was dependent on the *Cr*Arl13B concentration (Figure 2B and Table 1). Consistent with features of a typical GEF (Bos et al., 2007) Arl13B did not discriminate whether mantGppNHp or mantGDP was bound to Arl3 and exchanged both nucleotides with the same velocity (Table 2). As a control *Cr*Arl6 did not stimulate the nucleotide release of *Cr*Arl3 nor did *Cr*Arl3 catalyse that of *Cr*Arl113B (Figure 2C and 2B).
We next asked whether the nucleotide-bound state of CrArl13B affects its GEF activity as suggested by the GST-pull-down experiments. CrArl13B preloaded with GDP, GTP or GppNHp was used to analyse the exchange activity. At 5 µM GEF, the exchange was ~9fold slower for GDP- than for GTP- and GppNHp-bound CrArl13B (Figure 2E). The observed rate constants of mantGDP-dissociation showed a hyperbolic dependence on CrArl13B concentration, with a maximum release rate of 0.86x10⁻² sec⁻¹. The $K_M$ for the reaction is 1.1 µM for CrArl13B•GTP and 155 µM for CrArl13B•GDP (Figure 2F) showing that CrArl13B•GTP has a higher affinity than CrArl13B•GDP. Since the in vitro determined maximal nucleotide release stimulation of 70 fold appears relatively slow but not unusual, it is quite conceivable that additional factors such as the presence of membranes or lipids enhance the GEF activity as shown for the Ras-GEF SOS (Gureasko et al., 2008) and other GEFs (Cabrera et al., 2014; Pasqualato et al., 2002). Since Arl3 has a high affinity to membranes (Kapoor et al., 2015) and Arl13B is palmitoylated (Cevik et al., 2010) the reaction between them is thus most likely orchestrated on the ciliary membrane.

Next, we employed x-ray crystallography to elucidate the structural basis for the interaction. We thus co-crystallized CrArl13B•GppNHp and CrArl3•GDP in the presence of alkaline phosphatase in order to allow formation of nucleotide free CrArl3. Since CrArl13B requires bound nucleotide for stability (and most likely for activity) complex formation could not be performed with nucleotide free Arl3 GEF-substrate. The obtained crystals diffracted to 2.5Å and the structure was solved by molecular replacement showing one complex in the asymmetric unit (Table 3). Although crystallization was done in the presence of alkaline phosphatase GppNHp was clearly visible in both active sites, suggesting that the structure represents the post-nucleotide-exchange state. The nucleotide dependency of CrArl13B’s GEF activity suggested that switch I and II contribute to the interface. The structure shows indeed that a major part of the interaction is mediated by switch I and II of CrArl13B which contact CrArl3 via $\alpha^4_{Arl3}$, $\beta^6_{Arl3}$ and $\alpha^5_{Arl3}$ located opposite to the nucleotide binding site (Figure 3A and 3E). Further interactions are between the long $\alpha$-helix $\alpha^6_{Arl13B}$ which makes a 90° turn at residue G189, and $\alpha^3/\alpha^4_{Arl3}$. The last 58 residues, predicted to be $\alpha$-helical, are not visible in the electron density presumably because they are flexible.

To examine the interface we mutated residues within switch I, II and $\alpha6$ of CrArl13B (Figure 3B-D). Switch I mutant CrArl13B$^{F53A}$ showed a markedly decreased GEF activity whereas the D46A, F51A, N75A and Y83A mutants had only a minor effect (Figure 4A). The charge-reversal mutations K210E/R216E in $\alpha6_{Arl13B}$ as well as D103R and D146R in CrArl3 show no
activity, as expected, whereas a control mutation H154W outside the interface has no effect (Figure 4B). Since CrArl13B’s analogous Joubert mutation R77Q and to a lesser extent R194C have been shown to impair the conformational stability of switch II (Miertzschke et al., 2014), we next tested the analogous mutants CrArl13B\textsuperscript{R77Q} and CrArl13B\textsuperscript{R194C} for their GEF activities. CrArl13B\textsuperscript{R77Q} displayed a reduced activity in contrast to a very mild effect of CrArl13B\textsuperscript{R194C} (Figure 4C).

GEF proteins normally act by directly interfering with the nucleotide binding site thereby decreasing nucleotide affinity (Cherfils and Zeghouf, 2013). In the crystal structure the nucleotide binding site of CrArl3 is not directly contacted by CrArl13B. We were not able to trap the interacting residues presumably due to the presence of nucleotide and/or the flexibility of the interacting residues of Arl13B. Considering the length of the C-terminus required for catalysis (see below) it is however suggestive that the mobile C-terminus of Arl13B is involved in the GEF reaction by contacting the relevant surface of Arl3. To examine the importance of this region for catalysis we prepared deletion constructs with differing length of the α6-helix (see red asterisks in Figure 3A). Whereas the C-terminal deletion constructs Δ233(18-232) and Δ243(18-242) had no effect, a longer deletion to residue 220(18-219) showed a reduced stimulation (Figure 4D). Finally, the GEF activity of Δ213(18-212) and Δ203(18-202) was completely abolished. In support of their importance residues 212-228 are highly conserved among species and we would speculate that these residues contact Arl3 close to the nucleotide binding site.

We next decided to demonstrate the GEF activity of Arl13B in mammalian cells. Therefore we used a stably transfected IMCD3 cell line and transiently transfected HEK293 cells overexpressing human Arl13B-GFP. To quantify Arl3 activation, Arl3•GTP was affinity-precipitated with the effector GST-PDE6δ (Linari et al., 1999) and analysed by immunoblot. The level of endogenous Arl3•GTP was strikingly increased in cells overexpressing Arl13B compared to control cells (Figure 5A). Furthermore, the level of GTP-bound Arl3-Flag depended on the Arl13B concentration (Figure 5B). Consistent with the Y2H data the Arl2•GTP level was not affected by overexpressed Arl13B indicating selectivity for Arl3 (Figure 5G). Interface mutations in Arl13B which disrupted the in vitro exchange activity were also tested in HEK293 cells. Consistently, cells transfected with Arl13B\textsuperscript{K216E/R219E}, Arl13B\textsuperscript{Y55A} or Arl13B\textsuperscript{Y85A} did not markedly increase the Arl3•GTP level (Figure 5C, D). Intriguingly, the Arl3•GTP level in cells overexpressing the Joubert mutant variants Arl13B\textsuperscript{R79Q} and Arl13B\textsuperscript{R200C} was lower than those expressing Arl13B\textsuperscript{wt}. Consistent with the
biochemical data the R79Q mutation impaired Arl3 activation more pronounced than R200C (Figure 5E, F). Finally, we were able to purify human Arl13B (18-278) from insect cells in reasonable amounts to test its GEF activity. Confirming the conservation of structure and function the human Arl13B also exhibits strong GEF activity for Arl3 (Figure 6A). The stimulation of the nucleotide release was more efficient compared to CrArl13B, with a 900-fold acceleration at 5 µM. In agreement with the different biological function (Zhou et al., 2006), the nucleotide dissociation of Arl2 was not accelerated by Arl13B (Figure 6B).

Discussion

Arl13B has been implicated in a number of ciliary functions (Cevik et al., 2010; Humbert et al., 2012; Larkins et al., 2011; Li et al., 2010) and its deletion is causing multiple phenotypes such as the lethal hennin mouse mutant or the scorpion zebrafish mutant (Caspary et al., 2007; Sun et al., 2004). Here we describe a molecular function for Arl13B acting as GEF for Arl3 whereby the nucleotide state of Arl13B determines its catalytic activity in this activation cascade.

Our results have important implications for the regulation of sorting and transport processes into cilia. It has been shown before that Arl3 but not Arl2 can release ciliary cargo from the transport proteins PDE6δ and Unc119 (Ismail et al., 2012, 2011; Wright et al., 2011). One would predict that Arl3, which is enriched in cilia but also in other microtubule dense structures (Grayson et al., 2002; Zhou et al., 2006), is only activated inside cilia where Arl13B exclusively resides (Blacque et al., 2005; Caspary et al., 2007; Duldulao et al., 2009) in order to avoid release of ciliary prenylated and myristoylated cargo in the cytoplasm, where other cargo such as Ras, RheB, or Src kinases can be released by Arl2. The observation that expression of constitutive active ARL-3 (Q70L/Q72L) in L. donovani and in C. elegans resulted in decreased flagellum length and in impaired ciliogenesis might be explained by Arl3-GTP being located all over the cell and by subsequent mistargeting of proteins destined for the cilium. (Cuvillier et al., 2000; Li et al., 2010).

The different subcellular localization of Arl3-GAP and GEF resembles very closely the Ran driven nucleocytoplasmic transport system. Nucleocytoplasmic transport through the nuclear pore is regulated by a Ran gradient across the nuclear pore (Stewart, 2007). This gradient is regulated by the Ran-GEF RCC1 which is retained inside the nucleus and by the major form of Ran-GAP which is located at the exit side of the nuclear pore complex (NPC) by binding to RanBP2 (Mahajan et al., 1997). Import cargo bound to importins is released from the carrier by Ran•GTP. The export complex formed by the exportin-cargo complex is in turn stabilized
by Ran•GTP and dissociated after exit from the NPC and hydrolysis of GTP. Since the Arl3 specific GAP RP2 is absent from primary cilia and enriched in the preciliary region as observed by us and others (Blacque et al., 2005; Evans et al., 2010; Grayson et al., 2002), we can assume that a similar Arl3•GTP gradient exists across the transition zone and that the Arl3•GTP compartment inside cilia creates a driving force for the transport of prenylated and myristoylated proteins which are allosterically released by Arl3•GTP from their carrier proteins PDE6δ and Unc119a/b (see Figure 7 for a schematic overview). The Ran-GEF RCC1 is retained in the nucleus through its interaction with nucleosomes (Nemergut et al., 2001). In case of Arl13B the N-terminal palmitoylation site, but also the other domains seem to be indispensable for its ciliary localization and retention (Cevik et al., 2010; Duldulao et al., 2009).

Since Arl13B’s GEF activity is higher in the GTP-bound conformation one may ask if and how the nucleotide status of Arl13B itself is regulated. We have shown before that the intrinsic GTP hydrolysis activity of Arl13B is very low and that the protein active site does not contain a catalytic Glutamine residue (Miertzschke et al., 2014). Although we cannot exclude that an Arl13B specific GAP would supply catalytic residues an alternative explanation would be that Arl13B in the absence of GTP hydrolysis is mostly in the GTP-bound form. This does not exclude the existence of an Arl13B-GEF which is presently unknown.

Since both the mutations of the Arl3-GAP RP2 in Retinitis pigmentosa and the Arl3-GEF Arl13B in Joubert syndrome lead to ciliary defects and ciliopathies, we conclude that the amount of Arl3•GTP needs to be precisely regulated and that both an increase and decrease of Arl3•GTP is not tolerated for proper function of the cilium.
Material and Methods

Yeast techniques
Mouse retina cDNA library was generated according to “Mate&Plate” Library System User Manual (Clontech), cloned into pGADT7 (short: pAD) and introduced into *S. cerevisiae* Y187. Yeast techniques and two-hybrid methods were performed according to the Yeast Protocols Handbook and the Matchmaker GAL4 Two-Hybrid System 3 manual (Clontech) with *Saccharomyces cerevisiae* AH109. Murine Arl3ΔND129N (residues 17-182), Arl6ΔND133N (residues 16-186), Arl2ΔND128N (residues 17-184) and Arl13B (residue 20-278) were cloned into a Gateway compatible pBD-Gal4 vector (a kind gift from R. Roepman) and *S. cerevisiae* AH109 used as recipient for transformation.

Protein expression and purification
*C. reinhardtii* CrArl3B (UniProt: A8INQ0) and CrArl3 (UniProt: A8ISN6) were amplified by PCR from a cDNA library from *C. reinhardtii* CC-124 WT(wild-type)mt-[137c] [nit1, nit2, agg1] (a gift from T. Happe). Respective mutants were generated by site directed mutagenesis PCR. CrArl3 and CrArl13B proteins were expressed as GST-fusions and purified as previously described (Miertzschke et al., 2014). CrArl3 full length was additionally cloned into the pET20 vector to produce C-terminally His-tagged protein. Murine Arl3 full length (UniProt: Q9WUL7) and human Arl2 full length (Uniprot: P36404) in pET20 vectors were already available. Proteins were expressed in BL21DE3 CodonPlus RIL cells at 18°C after induction with 100µM IPTG. Purification of CrArl3-His, murine Arl3-His and human Arl2-His were conducted as described previously (Veltel et al., 2008). Human recombinant His-Arl13B 18-278 was expressed in High-Five insect cells for 66 hours at 27°C after virus infection. Insect cells were lysed in 30 mM Tris (pH7.5), 150 mM NaCl, 5 mM MgCl2, 3 mM β-Mercaptoethanol, 10% Glycerol and 0.1 mM GTP and Complete protease inhibitor cocktail (Roche) using a Microfluidizer M-110S (Microfluidics). Protein was purified by affinity chromatography using a Talon Superflow column (Clonetech) and size exclusion chromatography. All proteins were stored in buffer M containing 25 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 3 mM β-Mercaptoethanol and 1% Glycerol.

Preparation of proteins with defined nucleotide state
Nucleotide exchange to GDP, GTP, or (N-methylanthraniloyl) mantGDP on Arl proteins was performed in the presence of 50mM EDTA and a 5fold (2fold for mantGxP) excess of nucleotide. After incubation for 2hrs 100mM MgCl2 was added and the protein separated from the excess of nucleotide by a HiTrap desalting column (GE Healthcare). The nucleotide exchange to GppNHp and mantGppNHp was performed using agarose coupled alkaline phosphatase (AP). AP was removed by centrifugation and excess of nucleotide removed by a desalting column. The amount of protein-bound nucleotide was analyzed by C18 reversed-phase HPLC and quantified with a calibrator detector (Beckman Coulter) and an integrator (Shimadzu).

Pull-down assay with purified protein
Per sample 50 µg GST-CrArl3 was bound to 50 µl Glutathione agarose and washed 2x with 500 µl buffer M. GST-CrArl3 was incubated in 100 µl buffer M containing 1 mg/ml
CrAr13B\textsuperscript{18-278} (~37µM) for 30 minutes and afterwards washed 2x with 500 µl buffer M. Protein was eluted from beads by addition of SDS-loading buffer and subsequent boiling and analysed by SDS-PAGE.

**Crystallization, data collection and analysis**

CrAr13B•GppNHp and CrArl3•GDP (12mg/ml) were mixed in the presence of AP at a ratio 1:1.2 (Arl3:Arl13B). With the sitting drop/vapour diffusion method crystals appeared in 0.1M Tris pH 8.5, 25 % PEG 6000 (PEGII suite, Qiagen) after 3 days. Crystals were fished out of the 96 well plate and flash frozen in a cryo-solution containing the same constituents as the crystallization condition supplemented with 20 % glycerol. Data collection was done at the PXII-XS10SA beamline of the Swiss Light Source (SLS) Villingen. Data were indexed and processed with XDS(Kabsch, 1993).Molecular replacement was done with PHASER from the CCP4 package("The CCP4 suite: programs for protein crystallography.,” 1994). The structure refinement was done using phenix.refine of PHENIX (Adams et al., 2010). Images were generated with PYMOL (http://www.pymol.org). Atomic coordinates and structural factors have been deposited in the PDB under the accession code 5DI3.

**Guanine nucleotide exchange assay**

Nucleotide exchange reactions were performed in buffer M at 20°C. As standard conditions, 500 nM G-protein was incubated and the GEF reaction was started with the addition of a mix Arl13B and an excess of nucleotide. Unless otherwise stated 5 µM GEF was used. Since the species of the in excess added unlabeled G-nucleotide (GDP, GTP or GppNHp) does not influence the velocity of the GEF reaction, the mix always contained an 800fold excess of the respective nucleotide which was bound to Arl13B in order to avoid undesirable intrinsic nucleotide exchange of Arl13B. For the intrinsic dissociation the same volume buffer containing unlabeled nucleotide was added. The fluorescence change was monitored using a FluoroMax 4 Spectrofluorometer (Jobin Yvon) with an excitation at 366 nm and emission at 450 nm. Data was fitted to single exponential functions using Grafit5 (Erithacus software) to obtain the \( k_{off} \) values. All quantitative parameters were measured two or more times. To ensure that all CrAr13B mutants are 100% loaded with the same nucleotide, they were exchanged to GppNHp with alkaline phosphatase and the stimulation of the nucleotide release measured for CrArl3•mantGppNHp. \( K_M \) and \( V_{max} \) were obtained by fitting the data to the Michaelis Menten equation using Grafit5.

**Cells lines**

Mouse renal epithelial Flp-In cells from the inner medullary collecting duct (IMCD3 Flp-In; kind gift from M.V. Nachury) and HEK293 cells were cultured at 37 °C and 5 % CO\textsubscript{2} in DMEM/F12, HEPES (Life technologies) complemented with 10 % fetal bovine serum and 1 % L-Glutamine. The parental IMCD3 Flp-In cell line contains a stably integrated FRT cassette and was co-transfected with pOG44 coding a FLP recombinase and the appropriate pgLAP5 vector (Addgene) using Lipofectamine 2000 (Life technologies). For selection of successful stable genomic integration the media was supplemented with 200 µg/ml hygromycin (Merck) and
expression of the GFP-fusion protein was checked by Western Blot using an anti-GFP antibody (Santa Cruz Biotechnology).

Analysis of Arl13B GEF activity in whole cell lysates

For pull-downs of overexpressed Arl3-Flag 2.5x10^6 HEK293 cells were seeded in 15cm² dishes 24 hours prior to transfection. Cells were transfected using Polyethylenimine (PEI) at a ratio 3:1 of PEI (µg) : total DNA (µg). Cells were induced to ciliate by withdrawing serum for 30 hours. ~2.5x10^7 cells (1x15 cm² dish) were lysed in 1ml lysis buffer for 30 min at 4°C. For pull-downs of endogenous Arl3 1x10^8 cells (4x15 cm² dish) were used. Lysate was cleared by centrifugation and protein concentration normalized. Per sample 50 µg GST-PDE6δ was coupled to 50 µl Glutathione agarose which was incubated with cleared lysates 45 min at 4°C. Cleared lysate was removed and beads washed 2x with 500 µl buffer M. Samples were eluted with 1xSDS-loading buffer. For the detection of affinity-precipitated endogenous Arl3 an anti-Arl3 antibody (Novus Biologicals) was used, in case of Arl3-Flag an anti-Flag antibody (Thermo Scientific) was used. Expression of Arl13B-GFP was checked using an anti-GFP antibody (Santa Cruz Biotechnology) and antibody against S-peptide, which is located between Arl13B and GFP in pGLAP5. The level of Arl3•GTP was quantified using ImageJ. Experiments were repeated two or more times.

Acknowledgements

We thank Nadja Schröder for technical help and support to develop the mouse retina cDNA library. We especially thank the Dortmund Protein Facility of the MPI for purifying human Arl13B from insect cells. We are grateful to Raphael GASPER, Susanne Terheyden, Matthias Müller, David BIER, Stefan Baumeister, Ingrid VETTER and the SLS Beamline scientists Florian Dworkowski, Takashi Tomizaki and Anuschka Pauluhn for data collection at the Swiss Light Source, beamline PXII – X10SA, Paul Scherer Institute, Villigen, Switzerland. We thank Ronald Roepman and Steff Letteboer for providing yeast protocols and helpful suggestions. We thank Stefanie Koesling for the support in the tissue culture and Shehab ISMAIL for helpful discussions.

Funding

This work was supported by the European Research Council (ERC) Advanced Grant [Project title: ARCID; number 268782]. N.F. and A.G. were supported by grants from the Deutsche Forschungsgemeinschaft (GI 770/ 1-1), the funds of Hertha and Helmut Schmauser-Stiftung (Erlangen, Germany) and the Universitätsbund Erlangen-Nürnberg E.V. (Erlangen, Germany).
Table 1. $K_{\text{obs}}$ values from data shown in Figure 2B and 2E.

<table>
<thead>
<tr>
<th>Concentration dependency (Figure 2B)</th>
<th>$K_{\text{obs}}$ (s$^{-1}$) ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrArl3 wt intrinsic</td>
<td>1.2 x 10$^{-4}$ ± 1 x 10$^{-5}$</td>
</tr>
<tr>
<td>+ 0.25 µM CrArl13B GTP</td>
<td>1.3 x 10$^{-3}$ ± 2 x 10$^{-5}$</td>
</tr>
<tr>
<td>+ 0.5 µM CrArl13B GTP</td>
<td>2.7 x 10$^{-3}$ ± 3 x 10$^{-5}$</td>
</tr>
<tr>
<td>+ 5 µM CrArl13BGTP</td>
<td>0.85 x 10$^{-2}$ ± 1 x 10$^{-4}$</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nucleotide dependency (Figure 2E)</th>
<th>$K_{\text{obs}}$ (s$^{-1}$) ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrArl3 wt intrinsic</td>
<td>1.3 x 10$^{-4}$ ± 4 x 10$^{-6}$</td>
</tr>
<tr>
<td>+ 5 µM CrArl13B GDP</td>
<td>9.0 x 10$^{-4}$ ± 2 x 10$^{-5}$</td>
</tr>
<tr>
<td>+ 5 µM CrArl13B GTP</td>
<td>0.6 x 10$^{-2}$ ± 8 x 10$^{-5}$</td>
</tr>
<tr>
<td>+ 5 µM CrArl13B GNP</td>
<td>0.78 x 10$^{-2}$ ± 1 x 10$^{-4}$</td>
</tr>
</tbody>
</table>

$K_{\text{obs}}$ values ± standard error (S.E.) were determined by fitting the data to single exponential functions.

Table 2. $k_{\text{obs}}$ values for the nucleotide dissociation of CrArl3•mGDP and CrArl3•mGppNHp in the presence of CrArl13B•GTP.

<table>
<thead>
<tr>
<th>CrArl3•mGDP vs mGppNHp</th>
<th>$K_{\text{obs}}$ (s$^{-1}$) ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrArl3•mGDP intrinsic</td>
<td>1.3 x 10$^{-4}$ ± 2 x 10$^{-6}$</td>
</tr>
<tr>
<td>CrArl3•mGDP + 5 µM CrArl13B•GTP</td>
<td>0.84 x 10$^{-2}$ ± 7 x 10$^{-5}$</td>
</tr>
<tr>
<td>CrArl3•mGppNHp intrinsic</td>
<td>1.3 x 10$^{-4}$ ± 2 x 10$^{-6}$</td>
</tr>
<tr>
<td>CrArl3•mGppNHp + 5 µM CrArl13B•GTP</td>
<td>1.0 x 10$^{-2}$ ± 1 x 10$^{-4}$</td>
</tr>
</tbody>
</table>

$k_{\text{obs}}$ rates determined from GEF assays with 0.5 µM CrArl3 loaded with either mantGDP or mantGppNHp in the presence of 5 µM CrArl13B$^{18-278}$•GTP and 800µM unlabeled nucleotide.
Table 3. Data collection and refinement statistics (molecular replacement)

<table>
<thead>
<tr>
<th></th>
<th>CrArl13B-CrArl3 (5DI3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data collection</td>
<td></td>
</tr>
<tr>
<td>Space group</td>
<td>P212121</td>
</tr>
<tr>
<td>Cell dimensions</td>
<td></td>
</tr>
<tr>
<td>$a$, $b$, $c$ (Å)</td>
<td>57.10, 68.80, 120.00</td>
</tr>
<tr>
<td>$\alpha$, $\beta$, $\gamma$ (°)</td>
<td>90.00, 90.00, 90.00</td>
</tr>
<tr>
<td>Resolution (Å)</td>
<td>29.84 – 2.50 (2.60-2.50)</td>
</tr>
<tr>
<td>$R_{\text{merge}}$</td>
<td>0.07 (0.68)</td>
</tr>
<tr>
<td>$I / \sigma I$</td>
<td>17.56 (3.26)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>99.9 (99.9)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>6.4 (6.8)</td>
</tr>
</tbody>
</table>

| Refinement                   |                         |
| Resolution (Å)               | 2.50                    |
| No. reflections              | 16944 (1840)            |
| $R_{\text{work}} / R_{\text{free}}$ | 0.199/0.236           |
| No. atoms                    | 2995                    |
| Protein                      | 2900                    |
| Ligand/ion                   | 2 Mg$^{2+}$, 2 GMPPNP   |
| Water                        | 29                      |
| $B$-factors                  | 66                      |
| Protein                      | 66.40                   |
| Ligand/ion                   | 54.30                   |
| Water                        | 55.00                   |
| R.m.s. deviations            |                         |
| Bond lengths (Å)             | 0.005                   |
| Bond angles (°)              | 1.02                    |

*Values in parentheses are for highest-resolution shell.*
<table>
<thead>
<tr>
<th>CrAr13B Switch interface mutants</th>
<th>K&lt;sub&gt;obs&lt;/sub&gt; (s&lt;sup&gt;-1&lt;/sup&gt;) ± S.E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrAr3 intrinsic</td>
<td>1.4 x 10&lt;sup&gt;-4&lt;/sup&gt; ± 4 x 10&lt;sup&gt;-6&lt;/sup&gt;</td>
</tr>
<tr>
<td>+ 5 µM CrAr13B wt GTP</td>
<td>0.91 x 10&lt;sup&gt;-2&lt;/sup&gt; ± 2 x 10&lt;sup&gt;-4&lt;/sup&gt;</td>
</tr>
<tr>
<td>+ 5 µM CrAr13B F51A GTP</td>
<td>2.0 x 10&lt;sup&gt;-3&lt;/sup&gt; ± 2 x 10&lt;sup&gt;-5&lt;/sup&gt;</td>
</tr>
<tr>
<td>+ 5 µM CrAr13B Y83A GTP</td>
<td>4.2 x 10&lt;sup&gt;-4&lt;/sup&gt; ± 2 x 10&lt;sup&gt;-5&lt;/sup&gt;</td>
</tr>
<tr>
<td>+ 5 µM CrAr13B D46A GTP</td>
<td>0.9 x 10&lt;sup&gt;-3&lt;/sup&gt; ± 1 x 10&lt;sup&gt;-5&lt;/sup&gt;</td>
</tr>
<tr>
<td>+ 5 µM CrAr13B N75A GTP</td>
<td>4.1 x 10&lt;sup&gt;-3&lt;/sup&gt; ± 8 x 10&lt;sup&gt;-5&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Table 4. K<sub>obs</sub> values from data shown in Figure 4 A-D.

K<sub>obs</sub> values were determined by fitting the data (Figure 4 A-D) to single exponential functions. If not stated otherwise CrAr13B 18-278 is used for the measurements.
References


Figure 1. The interaction between Arl13B and Arl3 was identified in a Y2H screen. (A), Y2H interactions between Arl3ΔN\textsuperscript{D129N}\textsuperscript{pBD} and Arl13B\textsuperscript{1-270}\textsuperscript{pAD} and between Arl13B\textsuperscript{20-278}\textsuperscript{pBD} and Arl3\textsuperscript{pAD}. Transformed and mated cells were grown on –Leu –Trp medium. Interaction was verified on high stringency plates (–Leu –Trp –His –Ade) and with a β-galactosidase filter assay. (B), Interaction of Arl13B\textsuperscript{1-270}\textsuperscript{pAD} with Arl3\textsuperscript{ΔND129N}\textsuperscript{pBD}, Arl2\textsuperscript{ΔND128N}\textsuperscript{pBD} and Arl6\textsuperscript{ΔND133N}\textsuperscript{pBD} was analysed on low and high stringency plates. PDE6δ-pAD was used as positive control for Arl3 and Arl2. (C), Domain architecture of Arl13B, numbering derived from murine Arl13B (Mm: Mus musculus).

Figure 2. CrArl13B is the Guanine nucleotide exchange factor for CrArl3 (A), GST-pull-down assay with purified Chlamydomonas reinhardtii Arl proteins as indicated and described in detail in Methods. (B), GEF activity of the indicated concentrations of CrArl13B\textsuperscript{18-278} for 500 nM CrArl3•mantGDP. Arrow designates addition of CrArl13B and excess of unlabeled nucleotide. (C), CrArl13B•GppNHp but not CrArl6•GppNHp stimulates the nucleotide release of CrArl3•mantGppNHp. (D), CrArl3•GTP does not accelerate the nucleotide dissociation of CrArl13B•mantGppNHp. (E) GEF activity of 5 µM CrArl13B\textsuperscript{18-278} loaded with GDP (red), GTP (blue) or GppNHp (yellow). (F), Hyperbolic dependence of the observed rate constants for mantGDP release from 500 nM CrArl3 on CrArl13B•GTP or CrArl13B•GDP concentration. Fluorescence changes in time at each concentration of CrArl13B were fitted to single exponentials, and the resulting rate constants (k_{obs}) plotted against GEF concentration. K_{obs} values are summarized in Table 1.

Figure 3. The CrArl13B-CrArl3 complex. (A), The CrArl13B-CrArl3 complex structure with Arl13B (green), Arl3 (light blue), Switch I (blue), Switch II (red), GppNHp (yellow). Red asterisks delineate the deletion sites (V202, E212, K219) of CrArl13 used in the GEF assay below (Figure 4). Other deletion sites are not resolved in the electron density. Dashed line indicates the 58 C-terminal residues not visible in the structure (B)-(D), Details of the interaction interface. (C), hydrophobic residues located in Switch I and Switch II of CrArl13B are involved in the interaction with CrArl3. (D), K210 and R213 in α6\textsubscript{Arl13B} are forming salt bridges with D143\textsubscript{Arl3} and E103\textsubscript{Arl3}(orange). Coloring as in (A). (E) Schematic representation of residues located in the interface. Hydrogen bonds between residues are depicted as black dashed line, salt bridges as red dashed line.

Figure 4. Mutations in the CrArl13B-CrArl3 interface and Joubert mutations impair GEF activity. (A), GEF activity of CrArl13B\textsuperscript{18-278}•GppNHp switch I and II mutants. 5 µM of CrArl13B•GppNHp constructs and 800 µM unlabeled GppNHp were added to CrArl3•mantGppNHp (500 nM). (B), GEF assay with CrArl13B\textsuperscript{18-278}•GppNHp and CrArl3•mantGppNHp carrying charge reversal mutations located in the interface. (C), GEF activity of the analogous Joubert syndrome mutants (CrArl13B\textsuperscript{R77Q}, CrArl13B\textsuperscript{R194C}). Same concentrations as in a. (D), GEF assay with CrArl13B deletion constructs. Boundaries of deletion fragments: Δ203: 18-202; Δ213: 18-213; Δ220: 18-219; Δ229: 18-228; Δ233: 18-232. 18-278 is the construct used for all other GEF assays. K_{obs} values are summarized in Table 4.
Figure 5. Arl13B activates Arl3 in mammalian cells. (A), Endogenous Arl3•GTP was affinity-precipitated from HEK293 or IMCD3 cell lysates using GST-PDEδ and analysed as described in Methods. HEK293 cells were transiently transfected with full length Arl13B-GFP(pGLAP5); IMCD3 cells stably expressed the same construct. (B), HEK293 cells were transiently transfected with increasing amounts of Arl13B-GFP (0,1,3,6,12 µg DNA) and constant amounts of Arl3-Flag. Arl3•GTP level determined as in (A). (C), Arl3-Flag activation in the presence of wildtype and interface mutant Arl13B-GFP was determined as in (A) and quantified in (D). (E), Arl3-Flag activation in the presence Arl13B wt and Joubert syndrome mutants R79Q and R200C. (F), Quantification of (E). Data is represented as mean ± S.E. (G) Arl3-Flag and Arl2-Flag activation in the presence of Arl13B-GFP in HEK293 cells.

Figure 6. The GEF activity of human Arl13B is specific for Arl3. (A) GEF activity of human Arl13B18-278 (purified from insect cells) for murine Arl3. 5 µM hsArl13B•GTP and 800 µM GTP were added to 500 nM Arl3•mantGppNHp. k_{obs}(intrinsic): 4x10^{-4} s^{-1}, k_{obs}(Arl13B•GTP): 0,36 s^{-1}. (B) Human Arl13B•GTP does not accelerate nucleotide dissociation of Arl2•mantGppNHp. k_{obs}(intrinsic):1.2x10^{-2} s^{-1}; k_{obs}(Arl13B•GTP): 1.2x10^{-2} s^{-1}.

Figure 7. The targeting cycle of Arl3 dependent ciliary cargo. In the cilium where Arl13B resides Arl3 gets activated. Through the exclusive localization of Arl13B (Arl3-GEF) inside and RP2 (Arl3-GAP) outside the cilium an Arl3•GTP gradient is generated across the transition zone. The carriers PDEδ and Unc119a/b bound to ciliary lipidated cargo reach the cilium where Arl3•GTP binds to the carrier proteins and releases the cargo. RP2 - enriched in the preciliary region – stimulates the hydrolysis of Arl3•GTP which leads to the dissociation of the carrier proteins from Arl3•GDP.
Figure 2

A

### GST-CrArl3 Pull down

<table>
<thead>
<tr>
<th>Input</th>
<th>GST-CrArl3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
</tr>
<tr>
<td>GST-CrArl3:</td>
<td>- GDP GDP GNP GNP</td>
</tr>
<tr>
<td>CrArl13B:</td>
<td>GDP GNP GDP GNP GDP GNP</td>
</tr>
</tbody>
</table>

B

**CrArl3•mantGDP**

- intrinsic
- 0.25 μM
- 0.5 μM
- 5 μM

C

**CrArl3•mantGppNHp**

- intrinsic
- CrArl6
- CrArl13B

D

**CrArl13B•mantGppNHp**

- CrArl3•GTP
- intrinsic

E

**CrArl3•mantGDP**

- intrinsic
- CrArl13B•GDP
- CrArl13B•GTP/GppNHp

F

- $K_{diss} \text{ [s}^{-1}\text{]}$
- $CrArl13B \text{ [μM]}$

Graphs showing the decay of fluorescence over time for different concentrations and forms of CrArl3 and CrArl13B.